Circio Holding presented new preclinical data on its circular RNA platform, circVec, at the American Society of Gene and Cell Therapy meeting. In AAV-based gene therapies, the technology achieved up to a 40-fold increase in gene expression in heart tissue and up to a 50-fold increase in the eye.

According to the company, circVec leverages the greater stability of circular RNA to improve the effectiveness of gene therapy while reducing the need for high AAV doses, which may help lower the risk of side effects and treatment-related toxicity.

The data also showed consistent performance across different dose levels, highlighting the platform’s potential for treating inherited genetic and cardiac diseases. The company’s CEO, Erik Wiklund, stated that the circVec technology has attracted significant attention within the gene therapy industry.

https://www.drugtargetreview.com/circios-circular-rna-platform-shows-40-fold-gene-expression-boost/2135497.article